Here, we compared the utility of preoperative, peripheral blood–derived IFN-γ+ T-cell responses specific to carcinoembryonic antigen (CEA), 5T4, or control antigens (n = 64) with tumor staging and clinical details (n = 87) in predicting five-year outcome of CRC patients who underwent resection with curative intent. The gene discussed is IFNG; the disease is neoplasm.